Metabolomics for hematologic malignancies: Advances and perspective

被引:0
|
作者
Li, Xinglan [1 ]
Xu, Mengyu [1 ]
Chen, Yanying [2 ]
Zhai, Yongqing [3 ]
Li, Junhong [1 ]
Zhang, Ning [4 ]
Yin, Jiawei [5 ,6 ,7 ]
Wang, Lijuan [5 ,6 ,7 ,8 ]
机构
[1] Shandong Second Med Univ, Linyi Peoples Hosp, Linyi, Peoples R China
[2] Linyi Peoples Hosp, Hematol Lab, Linyi, Peoples R China
[3] Linyi Peoples Hosp, Dept Orthoped, Linyi, Peoples R China
[4] Linyi Peoples Hosp, Dept Anesthesiol, Linyi, Peoples R China
[5] Linyi Peoples Hosp, Cent Lab, Linyi, Peoples R China
[6] Key Lab Tumor Biol, Linyi, Peoples R China
[7] Xuzhou Med Univ, Key Lab Translat Oncol, Xuzhou, Peoples R China
[8] Linyi Peoples Hosp, Dept Hematol, Linyi, Peoples R China
关键词
amino acid metabolism; glucose metabolism; leukemia; lipid metabolism; lymphoma; myeloma; ACUTE MYELOID-LEUKEMIA; B-CELL LYMPHOMA; METABOLISM; SERUM; MICROENVIRONMENT; CHROMATOGRAPHY; PROLIFERATION; BIOMARKERS; SIGNATURE; RESISTANT;
D O I
10.1097/MD.0000000000039782
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
With the use of advanced technology, metabolomics allows for a thorough examination of metabolites and other small molecules found in biological specimens, blood, and tissues. In recent years, metabolomics has been recognized that is closely related to the development of malignancies in the hematological system. Alterations in metabolomic pathways and networks are important in the pathogenesis of hematologic malignancies and can also provide a theoretical basis for early diagnosis, efficacy evaluation, accurate staging, and individualized targeted therapy. In this review, we summarize the progress of metabolomics, including glucose metabolism, amino acid metabolism, and lipid metabolism in lymphoma, myeloma, and leukemia through specific mechanisms and pathways. The research of metabolomics gives a new insight and provides therapeutic targets for the treatment of patients with hematologic malignancies.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Hematologic malignancies
    Bernstein, I
    CURRENT OPINION IN HEMATOLOGY, 2000, 7 (04) : 203 - 204
  • [22] Hematologic Malignancies
    Tseng, Yolanda D.
    Ng, Andrea K.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (01) : 127 - +
  • [23] The evolution of NK cell immunotherapy for hematologic malignancies: A historical and contemporary perspective
    Daher, May
    Rezvani, Katayoun
    SEMINARS IN HEMATOLOGY, 2020, 57 (04) : 165 - 166
  • [24] Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: Why do it?
    Hale G.A.
    Current Hematologic Malignancy Reports, 2007, 2 (3) : 202 - 207
  • [25] The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective
    Baron, Frederic
    Storb, Rainer
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 637 - 653
  • [26] Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide
    Slack, JL
    Waxman, S
    Tricot, G
    Tallman, MS
    Bloomfield, CD
    ONCOLOGIST, 2002, 7 : 1 - 13
  • [27] New advances in the treatment of hematologic malignancies: Focus on topoisomerase I inhibitors - Introduction
    Kantarjian, H
    SEMINARS IN HEMATOLOGY, 1998, 35 (03) : 1 - 2
  • [28] Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities
    Huang, Feng
    Tian, Tian
    Wu, Yizhe
    Che, Jinxin
    Yang, Haiyan
    Dong, Xiaowu
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2021, 21 (09) : 1113 - 1122
  • [29] Thioredoxin and Hematologic Malignancies
    An, Ningfei
    Kang, Yubin
    REDOX AND CANCER, PT A, 2014, 122 : 245 - 279
  • [30] Hematologic malignancies in pregnancy
    Hurley, TJ
    McKinnell, JV
    Irani, MS
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2005, 32 (04) : 595 - +